HomeInsightsStock Comparison

Natco Pharma Ltd vs Pentokey Organy India Ltd Stock Comparison

Natco Pharma Ltd vs Pentokey Organy India Ltd Stock Comparison

Last Updated on: Aug 13, 2025

Key Highlights

  • The Latest Trading Price of Natco Pharma Ltd is ₹ 896.65 as of 13 Aug 13:26.
  • The P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 yearsThe P/E Ratio of Pentokey Organy (India) Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 yearsThe Market Cap of Pentokey Organy (India) Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Natco Pharma Ltd for the Jun '25 is ₹ 1390 crore as compare to the Mar '25 revenue of ₹ 1287 crore. This represent the growth of 8.02% The revenue of Pentokey Organy (India) Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Natco Pharma Ltd for the Jun '25 is ₹ 632.7 crore as compare to the Mar '25 ebitda of ₹ 614.4 crore. This represent the growth of 2.98% The ebitda of Pentokey Organy (India) Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 480.3 crore over 9 quarters. This represents a CAGR of 6.11% The net profit of Pentokey Organy (India) Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 yearsThe Dividend Payout of Pentokey Organy (India) Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Natco Pharma Ltd

  • Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited.
  • It became a deemed public company with effect from 1 July 1992.
  • The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993.
  • The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.

About Pentokey Organy (India) Ltd

  • Pentokey Organy (India) Ltd was incorporated on November 26, 1986.
  • The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
  • Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
  • Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
  • As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

Natco Pharma Ltd News Hub

News

Board of Natco Pharma recommends Interim Dividend

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 1...

Read more

12 Aug 2025 13:57

News

Natco Pharma to convene board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 August 202...

Read more

05 Aug 2025 15:21

News

Natco Pharma receives USFDA EIR for Hyderabad API facility

The US FDA had conducted an inspection at the company's aforementioned unit from 9 June to...

Read more

24 Jul 2025 15:09

News

Natco Pharma's API unit in Mekaguda clears USFDA inspection

Natco Pharma announced that the U.S.FDA has issued Establishment Inspection Report (EIR) f...

Read more

24 Jul 2025 15:34

News

Natco Pharma Ltd spurts 0.35%, gains for five straight sessions

Natco Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1036....

Read more

18 Jul 2025 13:00

News

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 ...

Read more

20 Jun 2025 09:54

Pentokey Organy (India) Ltd News Hub

News

Pentokey Organy (India) schedules board meeting

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 11...

Read more

06 Aug 2025 11:23

News

Pentokey Organy (India) schedules board meeting

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 24...

Read more

21 May 2025 20:05

News

Pentokey Organy (India) to discuss results

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 25...

Read more

22 Jan 2025 14:33

News

Pentokey Organy (India) AGM scheduled

Pentokey Organy (India) announced that the Annual General Meeting (AGM) of the company wil...

Read more

12 Aug 2024 15:56

News

Pentokey Organy (India) to declare Quarterly Result

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 10...

Read more

07 Aug 2024 12:36

News

Pentokey Organy (India) announces board meeting date

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 13...

Read more

08 May 2024 10:47

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Pentokey Organy (India) Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Pentokey Organy (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Natco Pharma Ltd and Pentokey Organy (India) Ltd

Which company has a larger market capitalization, Natco Pharma Ltd or Pentokey Organy (India) Ltd?

Market cap of Natco Pharma Ltd is 15,902 Cr while Market cap of Pentokey Organy (India) Ltd is 28 Cr

What are the key factors driving the stock performance of Natco Pharma Ltd and Pentokey Organy (India) Ltd?

The stock performance of Natco Pharma Ltd and Pentokey Organy (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Natco Pharma Ltd and Pentokey Organy (India) Ltd?

As of August 13, 2025, the Natco Pharma Ltd stock price is INR ₹887.85. On the other hand, Pentokey Organy (India) Ltd stock price is INR ₹44.75.

How do dividend payouts of Natco Pharma Ltd and Pentokey Organy (India) Ltd compare?

To compare the dividend payouts of Natco Pharma Ltd and Pentokey Organy (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions